Krystal Biotech (KRYS) R&D president sells 25,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Krystal Biotech President of R&D and director Suma Krishnan sold 25,000 shares of the company’s common stock on March 4, 2026 in open-market trades under a pre-arranged Rule 10b5-1 trading plan. The reported sales occurred at prices between $256.68 and $266.93 per share.

After these transactions, she directly held 1,403,155 shares of Krystal Biotech common stock. She also had indirect ownership of 90,000 shares through SMK Trust and 50,000 shares through the Krishnan Family Trust, where she and her spouse are joint beneficial owners with joint voting and investment control.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krishnan Suma

(Last) (First) (Middle)

C/O KRYSTAL BIOTECH, INC.

2100 WHARTON STREET, SUITE 701

(Street)

PITTSBURGH PA 15203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		S(1)		407(2)	D	$257.3186(3)	1,427,748	D
Common Stock	03/04/2026		S		589	D	$258.5404(4)	1,427,159	D
Common Stock	03/04/2026		S		668	D	$259.6095(5)	1,426,491	D
Common Stock	03/04/2026		S		3,667	D	$260.3661(6)	1,422,824	D
Common Stock	03/04/2026		S		2,931	D	$261.4119(7)	1,419,893	D
Common Stock	03/04/2026		S		1,938	D	$262.3479(8)	1,417,955	D
Common Stock	03/04/2026		S		2,248	D	$263.5831(9)	1,415,707	D
Common Stock	03/04/2026		S		4,852	D	$264.6371(10)	1,410,855	D
Common Stock	03/04/2026		S		6,000	D	$265.1632(11)	1,404,855	D
Common Stock	03/04/2026		S		1,700	D	$266.4224(12)	1,403,155	D
Common Stock								90,000	I	By SMK Trust
Common Stock								50,000	I	By Krishnan Family Trust(13)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.

2. The sales reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

3. The transaction was executed in multiple trades ranging from $256.68 to $257.67. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

4. The transaction was executed in multiple trades ranging from $257.93 to $258.92. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

5. The transaction was executed in multiple trades ranging from $258.98 to $259.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

6. The transaction was executed in multiple trades ranging from $259.98 to $260.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

7. The transaction was executed in multiple trades ranging from $261 to $261.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

8. The transaction was executed in multiple trades ranging from $262 to $262.8. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

9. The transaction was executed in multiple trades ranging from $263 to $263.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

10. The transaction was executed in multiple trades ranging from $264 to $264.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

11. The transaction was executed in multiple trades ranging from $265 to $265.73. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

12. The transaction was executed in multiple trades ranging from $266 to $266.93. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

13. Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control, and holdings and transactions by the Krishnan Family Trust are also reflected on the separate Form 4 filed by her spouse.

Remarks:

	/s/ Suma M. Krishnan	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Krystal Biotech (KRYS) report for Suma Krishnan?

Krystal Biotech reported that President of R&D and director Suma Krishnan sold 25,000 shares of common stock on March 4, 2026. These were open-market sales executed across multiple trades at prices between $256.68 and $266.93 per share under a Rule 10b5-1 plan.

How many Krystal Biotech (KRYS) shares does Suma Krishnan hold after the March 4, 2026 sale?

After the March 4, 2026 transactions, Suma Krishnan directly held 1,403,155 shares of Krystal Biotech common stock. She also had indirect ownership of 90,000 shares through SMK Trust and 50,000 shares through the Krishnan Family Trust, according to the Form 4 disclosure.

Was the Krystal Biotech (KRYS) insider sale by Suma Krishnan under a Rule 10b5-1 plan?

Yes. The Form 4 states the sales were made under a Rule 10b5-1 trading plan adopted on September 4, 2025. The plan began December 4, 2025 and is scheduled to terminate on December 4, 2026, or earlier under its specified terms.

What price range did Suma Krishnan’s Krystal Biotech (KRYS) share sales cover?

The reported transactions were executed in multiple trades with weighted average prices. Footnotes state trade ranges from $256.68 to $266.93 per share across different sale blocks, with the Form 4 noting that detailed trade-level data is available upon request.

How are Krystal Biotech (KRYS) shares held indirectly by Suma Krishnan reported?

The Form 4 reports 90,000 shares held indirectly through SMK Trust and 50,000 shares held indirectly through the Krishnan Family Trust. It notes that she and her spouse are joint beneficial owners of the Krishnan Family Trust, with joint voting and investment control over those shares.

Are transactions by Suma Krishnan’s spouse in Krystal Biotech (KRYS) shares included in this Form 4?

No. A footnote explains that shares directly owned and transactions by her spouse, Krish S. Krishnan, are reported separately on his own Form 4. Suma Krishnan disclaims beneficial ownership of those shares except to the extent of her pecuniary interest.